Stereotaxis Inc. (NYSEAMERICAN:STXS) Short Interest Up 21.2% in February

Stereotaxis Inc. (NYSEAMERICAN:STXS) was the target of a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling 3,271,536 shares, a growth of 21.2% from the January 29th total of 2,699,750 shares. Currently, 4.3% of the shares of the stock are short sold. Based on an average daily volume of 542,840 shares, the days-to-cover ratio is currently 6.0 days. Based on an average daily volume of 542,840 shares, the days-to-cover ratio is currently 6.0 days. Currently, 4.3% of the shares of the stock are short sold.

Institutional Trading of Stereotaxis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Lagoda Investment Management L.P. increased its stake in shares of Stereotaxis by 0.4% during the 3rd quarter. Lagoda Investment Management L.P. now owns 4,707,400 shares of the company’s stock valued at $14,640,000 after acquiring an additional 19,500 shares during the last quarter. Vanguard Group Inc. grew its holdings in Stereotaxis by 4.2% in the third quarter. Vanguard Group Inc. now owns 3,441,091 shares of the company’s stock valued at $10,702,000 after purchasing an additional 138,482 shares during the period. Arbiter Partners Capital Management LLC increased its position in Stereotaxis by 1.1% during the fourth quarter. Arbiter Partners Capital Management LLC now owns 2,883,856 shares of the company’s stock worth $6,633,000 after purchasing an additional 30,000 shares during the last quarter. Essex Investment Management Co. LLC raised its stake in Stereotaxis by 3.5% during the third quarter. Essex Investment Management Co. LLC now owns 1,598,114 shares of the company’s stock worth $4,970,000 after purchasing an additional 53,358 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Stereotaxis by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 1,565,182 shares of the company’s stock valued at $3,601,000 after purchasing an additional 55,491 shares during the last quarter. Hedge funds and other institutional investors own 45.35% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Citigroup started coverage on Stereotaxis in a research note on Tuesday, December 16th. They issued an “outperform” rating on the stock. Roth Mkm reissued a “buy” rating and issued a $4.00 price target on shares of Stereotaxis in a report on Wednesday, November 12th. Citizens Jmp assumed coverage on Stereotaxis in a research note on Tuesday, December 16th. They set a “market outperform” rating and a $4.00 price objective on the stock. Finally, UBS Group set a $4.00 target price on shares of Stereotaxis in a research note on Wednesday, November 5th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $4.00.

Stereotaxis Stock Down 3.6%

Shares of Stereotaxis stock opened at $2.14 on Wednesday. Stereotaxis has a fifty-two week low of $1.54 and a fifty-two week high of $3.59. The business’s fifty day moving average is $2.33 and its two-hundred day moving average is $2.60. The firm has a market cap of $199.70 million, a PE ratio of -7.64 and a beta of 1.38.

About Stereotaxis

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.